Collectively, these results also highlight the additional potential for using RNAMethyPro as a tool for predicting therapeutic response to anti-EGFR therapy, which will refine and further optimize treatment decision-making in metastatic CRC patients. Here, EGFR is linked to colorectal carcinoma.